Ofer Mandelboim

Title: Ofer Mandelboim: Innovator in Cancer Immunotherapy

Introduction

Ofer Mandelboim, a prominent inventor located in Shoham, Israel, has made significant contributions to the field of immunology and cancer therapy. With a portfolio of 9 patents, his work primarily focuses on innovative approaches to enhance immune response against tumors using monoclonal antibodies.

Latest Patents

Mandelboim's latest patents highlight groundbreaking advancements in cancer immunotherapy. One of his notable inventions details antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT). This patent illustrates how the natural killer (NK) cell killing of various tumors is inhibited in the presence of TIGIT ligands. His work provides monoclonal antibodies that target TIGIT, thereby inhibiting its suppressive effects on T-cells. These antibodies are accompanied by pharmaceutical compositions and methodologies for their application in cancer immunotherapy and for diagnosing and treating immune disorders.

Another significant patent involves antibodies specific to human NECTIN4. This invention focuses on monoclonal antibodies that exhibit high affinity and specificity towards human Nectin4, inhibiting its interaction with TIGIT. This research also includes pharmaceutical compositions and methods for utilizing these antibodies in cancer immunotherapy and diagnosis.

Career Highlights

Mandelboim has been affiliated with several notable research institutions throughout his career. He has worked with the Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., as well as the Ben-Gurion University of the Negev Research and Development Authority. His work in these esteemed organizations underscores his commitment to advancing scientific research and innovation in the medical field.

Collaborations

Throughout his career, Mandelboim has collaborated with renowned professionals in his field. Notable colleagues include Pinchas Tsukerman and Stipan Jonjic. These collaborations have fostered a rich environment for knowledge exchange and have contributed significantly to Mandelboim's innovative research efforts.

Conclusion

Ofer Mandelboim stands as an influential inventor in the realm of cancer immunotherapy. His extensive patent portfolio and dedication to research exemplify the potential of targeted immunological treatments. With continued collaborations and innovative breakthroughs, Mandelboim's contributions are poised to have a lasting impact on the future of cancer treatment.